Drugs / Janssen Ad26.COV2.S
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05844202 Comparator | Jun 2022 → Mar 2023 | COVID-19 | Alvea Holdings, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Janssen Ad26.COV2.S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844202 ↗ |
| Modality | Vaccine | “COVID-19 vaccine” NCT05844202 ↗ |
| Route | Intramuscular | “one intramuscular (IM) injection” NCT05844202 ↗ |